Literature DB >> 22240432

The MCP-1 (CCL2) -2518 GG genotype is associated with protection against pulmonary tuberculosis in Moroccan patients.

Naima Arji1, Marc Busson, Ghali Iraqi, Jamal Eddine Bourkadi, Abdelaziz Benjouad, Wahid Boukouaci, Ouafae Lahlou, Jouda Ben Amor, Rajagopal Krishnamoorthy, Dominique Charron, Rajae El Aouad, Ryad Tamouza.   

Abstract

INTRODUCTION: Both monocyte chemoattractant protein-1 (MCP-1), also designated officially as chemokine (C-C motif) ligand 2 (CCL2), and interleukin-12 p40 (IL-12 p40) molecules, encoded by polymorphic genes, are central components of the immune response to infection by Mycobacterium tuberculosis (Mtb). Their genetic diversity has previously been associated with the outcome of tuberculosis (TB) infection. We investigated whether the MCP-1 -2518 A/G and the IL-12B (p40) +1188 A/C polymorphisms influence susceptibility to or resistance against pulmonary tuberculosis (PTB) in a Moroccan population group.
METHODOLOGY: Genomic DNA from 337 patients along with 204 healthy controls were genotyped for the above-mentioned genetic variations using polymerase chain reaction-based restriction fragment length polymorphism assay.
RESULTS: We found a higher prevalence of homozygous MCP-1 -2518 G allele in healthy individuals than in patients (pc = 0.04; odds ratio  = 0.35; 95% confidence interval  = 0.13 - 0.86), suggesting a potential protective effect, whereas analysis of IL-12B +1188 variation failed to reveal any such association.
CONCLUSION: Our results are in agreement with recent findings in Ghanaian patients, complying with the known genetic admixture of the Moroccan population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240432     DOI: 10.3855/jidc.1925

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  7 in total

1.  A MCP-1 promoter polymorphism at G-2518A is associated with spontaneous preterm birth.

Authors:  Yan Wang; Xiao-Ai Zhang; Xiao Yang; Zhi-Hao Wu; Zhi-Chun Feng
Journal:  Mol Genet Genomics       Date:  2014-09-19       Impact factor: 3.291

2.  Genomics of human pulmonary tuberculosis: from genes to pathways.

Authors:  Catherine M Stein; Lindsay Sausville; Christian Wejse; Rafal S Sobota; Nicola M Zetola; Philip C Hill; W Henry Boom; William K Scott; Giorgio Sirugo; Scott M Williams
Journal:  Curr Genet Med Rep       Date:  2017-10-12

3.  MCP1 SNPs and pulmonary tuberculosis in cohorts from West Africa, the USA and Argentina: lack of association or epistasis with IL12B polymorphisms.

Authors:  Digna R Velez Edwards; Alessandra Tacconelli; Christian Wejse; Philip C Hill; Gerard A J Morris; Todd L Edwards; John R Gilbert; Jamie L Myers; Yo Son Park; Martin E Stryjewski; Eduardo Abbate; Rosa Estevan; Paulo Rabna; Giuseppe Novelli; Carol D Hamilton; Richard Adegbola; Lars Østergaar; Scott M Williams; William K Scott; Giorgio Sirugo
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

4.  The CYP7A1 gene rs3808607 variant is associated with susceptibility of tuberculosis in Moroccan population.

Authors:  Mounia Qrafli; Youssef Amar; Jamaleddine Bourkadi; Jouda Ben Amor; Ghali Iraki; Youssef Bakri; Saaîd Amzazi; Ouafae Lahlou; Fouad Seghrouchni; Rajae El Aouad; Khalid Sadki
Journal:  Pan Afr Med J       Date:  2014-05-01

5.  Genetic association meta-analysis: a new classification to assess ethnicity using the association of MCP-1 -2518 polymorphism and tuberculosis susceptibility as a model.

Authors:  Tania Vásquez-Loarte; Milana Trubnykova; Heinner Guio
Journal:  BMC Genet       Date:  2015-10-30       Impact factor: 2.797

Review 6.  Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.

Authors:  Murugesan Harishankar; Paramasivam Selvaraj; Ramalingam Bethunaickan
Journal:  Front Med (Lausanne)       Date:  2018-08-16

7.  Gaps in Study Design for Immune Parameter Research for Latent Tuberculosis Infection: A Systematic Review.

Authors:  Mariana Herrera; Cristian Vera; Yoav Keynan; Zulma Vanessa Rueda
Journal:  J Immunol Res       Date:  2020-04-21       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.